A Registry Study of Patients Hospitalized With Confirmed COVID-19
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 488
- 主要终点
- Disease progression rates
研究概览
简要总结
The design of this registered study aims to evaluate the efficacy and safety of Paxlovid in the treatment of hospitalized COVID-19 patients, and to explore factors related to the efficacy and safety of Paxlovid.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of COVID-19 infection.
- •Presence of at least one high-risk factor, including age ≥60 years, diabetes, hypertension, cardiovascular disease, stroke, chronic liver or kidney disease, cancer, history of smoking or obesity.
排除标准
- •No specific exclusion criteria in this study.
研究组 & 干预措施
No paxlovid used
Patients have never used Paxlovid after being diagnosed with COVID-19, whether before or after hospitalization.
干预措施: No paxlovid (Drug)
Paxlovid （More than 5 days after the diagnosis of COVID-19）
According to the patient's medical records, the time from the diagnosis of COVID-19 to the prescription of PAXLOVID exceeds 5 days.
干预措施: Paxlovid (Drug)
Paxlovid（Within 5 days after the diagnosis of COVID-19）
According to the patient's medical records, the time from the diagnosis of COVID-19 to the prescription of PAXLOVID is within 5 days.
干预措施: Paxlovid (Drug)
结局指标
主要结局
Disease progression rates
时间窗: up to 28 days
The proportion of patients who experienced any of the following events within 28 days after being diagnosed with COVID-19, including all-cause mortality, requiring invasive mechanical ventilation, or being admitted to the intensive care unit.
次要结局
- all-cause deaths rates(up to 28 days)
- rehospitalization event rates(up to 28 days)
- adverse drug reaction event(up to 28 days)
- COVID-19 repositive event rates(up to 28 days)
- thromboembolic event rates(up to 28 days)
研究者
Zhang Yi
professer
Beijing Chao Yang Hospital